| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Christine Börner, Andrea Bedini, Volker Höllt, Jürgen Krau. Analysis of promoter regions regulating basal and interleukin-4-inducible expression of the human CB1 receptor gene in T lymphocytes. Molecular pharmacology. vol 73. issue 3. 2008-04-07. PMID:18156315. |
the majority of effects of cannabinoids are mediated by the two receptors cb1 and cb2. |
2008-04-07 |
2023-08-12 |
human |
| Afa K Palu, Anne Hirazumi Kim, Brett J West, Shixin Deng, Jarakae Jensen, Leland Whit. The effects of Morinda citrifolia L. (noni) on the immune system: its molecular mechanisms of action. Journal of ethnopharmacology. vol 115. issue 3. 2008-04-03. PMID:18063495. |
in vitro, tahitian noni juice (tnj) and noni fruit juice concentrates (nfjc) (1, 5mg/ml) potently activate cannabinoid 2 (cb2), but inhibit cannabinoid 1 (cb1) receptors in a concentration-dependant manner. |
2008-04-03 |
2023-08-12 |
mouse |
| M Maccarron. CB2 receptors in reproduction. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828289. |
this review will focus on the involvement of type-2 cannabinoid (cb2) receptors in reproductive biology, covering both the male and female sides. |
2008-04-02 |
2023-08-12 |
mouse |
| M Maccarron. CB2 receptors in reproduction. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828289. |
it will also discuss the potential relevance of the immunological activity of cb2 at the maternal/foetal interface, as well as the distinctiveness of cb2 versus type-1 cannabinoid (cb1) receptors that might be exploited for a receptor subtype-specific regulation of fertility. |
2008-04-02 |
2023-08-12 |
mouse |
| R G Pertwe. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828291. |
the diverse cb1 and cb2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. |
2008-04-02 |
2023-08-12 |
Not clear |
| R G Pertwe. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828291. |
this review focuses on the manner with which three of these compounds, (-)-trans-delta9-tetrahydrocannabinol (delta9-thc), (-)-cannabidiol (cbd) and (-)-trans-delta9-tetrahydrocannabivarin (delta9-thcv), interact with cannabinoid cb1 and cb2 receptors. |
2008-04-02 |
2023-08-12 |
Not clear |
| R G Pertwe. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828291. |
delta9-thc, the main psychotropic constituent of cannabis, is a cb1 and cb2 receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by the expression level and signalling efficiency of cannabinoid receptors and by ongoing endogenous cannabinoid release. |
2008-04-02 |
2023-08-12 |
Not clear |
| R G Pertwe. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828291. |
brief mention is also made in this review, first of the production by delta9-thc of pharmacodynamic tolerance, second of current knowledge about the extent to which delta9-thc, cbd and delta9-thcv interact with pharmacological targets other than cb1 or cb2 receptors, and third of actual and potential therapeutic applications for each of these cannabinoids. |
2008-04-02 |
2023-08-12 |
Not clear |
| A Arévalo-Martín, D García-Ovejero, O Gómez, A Rubio-Araiz, B Navarro-Galve, C Guaza, E Molina-Holgado, F Molina-Holgad. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17891163. |
cb2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. |
2008-04-02 |
2023-08-12 |
Not clear |
| A Arévalo-Martín, D García-Ovejero, O Gómez, A Rubio-Araiz, B Navarro-Galve, C Guaza, E Molina-Holgado, F Molina-Holgad. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17891163. |
cannabinoids are well known immunomodulatory molecules that act through cb1 and cb2 receptors. |
2008-04-02 |
2023-08-12 |
Not clear |
| K L Wright, M Duncan, K A Sharke. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906675. |
cannabinoid cb2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. |
2008-04-02 |
2023-08-12 |
Not clear |
| C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell, L Bobe. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906679. |
biology and therapeutic potential of cannabinoid cb2 receptor inverse agonists. |
2008-04-02 |
2023-08-12 |
human |
| C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell, L Bobe. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906679. |
evidence has emerged suggesting a role for the cannabinoid cb2 receptor in immune cell motility. |
2008-04-02 |
2023-08-12 |
human |
| C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell, L Bobe. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906679. |
this provides a rationale for a novel and generalized immunoregulatory role for cannabinoid cb2 receptor-specific compounds. |
2008-04-02 |
2023-08-12 |
human |
| C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell, L Bobe. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906679. |
in support of this possibility, we will review the biology of a class of cannabinoid cb2 receptor-specific inverse agonist, the triaryl bis-sulfones. |
2008-04-02 |
2023-08-12 |
human |
| C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell, L Bobe. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906679. |
we will show that one candidate, sch.414319, is potent and selective for the cannabinoid cb2 receptor, based on profiling studies using biochemical assays for 45 enzymes and 80 g-protein coupled receptors and ion channels. |
2008-04-02 |
2023-08-12 |
human |
| C Benito, R M Tolón, M R Pazos, E Núñez, A I Castillo, J Romer. Cannabinoid CB2 receptors in human brain inflammation. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17934510. |
cannabinoid cb2 receptors in human brain inflammation. |
2008-04-02 |
2023-08-12 |
human |
| C Benito, R M Tolón, M R Pazos, E Núñez, A I Castillo, J Romer. Cannabinoid CB2 receptors in human brain inflammation. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17934510. |
the presence of functional cannabinoid cb2 receptors in the cns has provoked considerable controversy over the past few years. |
2008-04-02 |
2023-08-12 |
human |
| S Lotersztajn, F Teixeira-Clerc, B Julien, V Deveaux, Y Ichigotani, S Manin, J Tran-Van-Nhieu, M Karsak, A Zimmer, A Malla. CB2 receptors as new therapeutic targets for liver diseases. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17952109. |
cannabinoid type-1 (cb1) and type-2 (cb2) receptors belong to the family of g protein-coupled receptors and mediate biological effects of phyto-derived and endogenous cannabinoids. |
2008-04-02 |
2023-08-12 |
Not clear |
| N Rimmerman, H V Hughes, H B Bradshaw, M X Pazos, K Mackie, A L Prieto, J M Walke. Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17965731. |
n-arachidonoyl ethanolamine (aea) and 2-arachidonoyl glycerol (2-ag) are endogenous cannabinoids binding to the cannabinoid receptors cb1 and cb2 to modulate neuronal excitability and synaptic transmission in primary afferent neurons. |
2008-04-02 |
2023-08-12 |
Not clear |